Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Wednesday

Akebia Therapeutics (NASDAQ:AKBA) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Akebia Therapeutics to post earnings of ($0.03) per share and revenue of $48.8520 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Akebia Therapeutics (NASDAQ:AKBA) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.02). Akebia Therapeutics had a negative net margin of 8.83% and a negative return on equity of 62.72%. The company had revenue of $53.54 million for the quarter, compared to analyst estimates of $51.67 million. On average, analysts expect Akebia Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Akebia Therapeutics Stock Performance

Shares of AKBA opened at $1.32 on Monday. Akebia Therapeutics has a 12-month low of $0.82 and a 12-month high of $3.79. The firm has a market capitalization of $354.10 million, a price-to-earnings ratio of -16.50 and a beta of 0.26. The stock’s 50-day moving average price is $1.15 and its 200 day moving average price is $1.27. The company has a quick ratio of 1.33, a current ratio of 1.40 and a debt-to-equity ratio of 1.33.

Insider Buying and Selling

In other Akebia Therapeutics news, CFO Erik Ostrowski sold 56,019 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $1.11, for a total transaction of $62,181.09. Following the completion of the sale, the chief financial officer directly owned 616,616 shares of the company’s stock, valued at approximately $684,443.76. The trade was a 8.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Akebia Therapeutics

Several institutional investors have recently modified their holdings of the business. Baird Financial Group Inc. raised its stake in shares of Akebia Therapeutics by 23.0% during the first quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 4,000 shares during the last quarter. Legal & General Group Plc grew its holdings in Akebia Therapeutics by 26.0% during the 2nd quarter. Legal & General Group Plc now owns 23,279 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 4,798 shares during the period. Polymer Capital Management US LLC raised its position in shares of Akebia Therapeutics by 49.5% during the 3rd quarter. Polymer Capital Management US LLC now owns 18,232 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 6,034 shares during the last quarter. Deutsche Bank AG raised its position in shares of Akebia Therapeutics by 5.2% during the 4th quarter. Deutsche Bank AG now owns 164,655 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 8,103 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its stake in shares of Akebia Therapeutics by 16.8% in the 2nd quarter. Raymond James Financial Inc. now owns 59,502 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 8,568 shares during the period. Institutional investors and hedge funds own 33.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Akebia Therapeutics in a report on Wednesday, July 1st. Wall Street Zen lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akebia Therapeutics in a report on Wednesday, May 6th. Zacks Research upgraded Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, BTIG Research reissued a “buy” rating and issued a $4.00 price objective on shares of Akebia Therapeutics in a research note on Tuesday, April 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.67.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.